The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
It should be noted that the ATLAS patient population had almost no squamous cell carcinoma, in contrast to the populations of the JMEN pemetrexed trial and the SATURN erlotinib trial.